Table 3.
Change of treatment in men initially prescribed an α-blocker plus an antimuscarinic combination treatment and non-persistent at 12 months
| FDC | Concomitant therapy | |
|---|---|---|
| Change of treatment in men non-persistent at 12 months, N (%) | N = 324 | N = 859 |
| Switcha | 19 (5.9) | 56 (6.5) |
| No switch/discontinuationb | 305 (94.1) | 803 (93.5) |
| Switched to, N (%) | N = 19 | N = 56 |
| Combination with new α-blocker | 1 (5.3) | 5 (8.9) |
| Combination with new antimuscarinic | 6 (31.6) | 25 (44.6) |
| Concomitant therapy with the same drugs | 9 (47.4) | 3 (5.4) |
| Concomitant therapy with a new α-blocker and antimuscarinic | 3 (15.8) | 0 |
| FDC | 0 | 23 (41.1) |
| No switch/discontinuation, N (%) | N = 305 | N = 803 |
| α-blocker therapy only | 58 (19.0) | 246 (30.6) |
| Antimuscarinic therapy only | 19 (6.2) | 107 (13.3) |
| No therapy changes | 228 (74.8) | 450 (56.0) |
FDC fixed-dose combination
aAlternative combination therapy prescribed within 30 days following discontinuation of index combination therapy
bNo alternative combination therapy prescribed within 30 days following discontinuation of index combination therapy